H.C. Wainwright Reiterates Buy Rating on Zevra Therapeutics, Inc. (ZVRA)

H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating and $26.00 price target on Zevra Therapeutics, Inc. (NASDAQ: ZVRA).

The analyst commented: "ZVRA’s additional Orange Book patent for MIPLYFFA meaningfully improves the investment setup, in our view, by extending listed patent protection to late 2041 and directly addressing what we believe has been the primary overhang on the stock: visibility into the product’s post-2031 exclusivity runway. We continue to believe the company is executing well on the U.S. MIPLYFFA launch, while the EU opportunity and potential U.S. celiprolol approval remain additional upside drivers not fully reflected in the current valuation. With MIPLYFFA already building into a durable rare disease revenue base, a strong balance sheet, and the potential for meaningful cash flow generation over the next several years, the longer IP runway strengthens the case that ZVRA’s current market value does not fully capture the durability of the asset or the strategic value of the platform. We reiterate our Buy rating and $26 price target."

For an analyst ratings summary and ratings history on Zevra Therapeutics, Inc. click here. For more ratings news on Zevra Therapeutics, Inc. click here.

Shares of Zevra Therapeutics, Inc. closed at $12.09 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy